The CD300C Knockout HAP1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population targeting the CD300C gene in the HAP1 host. This pool contains a heterogeneous mix of gene-disrupted alleles, enabling robust functional studies without clonal artifacts. The loss-of-function model facilitates dissection of CD300C-mediated signaling in a simplified haploid genomic setting.
HAP1 is a near-haploid human male chronic myeloid leukemia (CML) cell line derived from KBM-7. Its predominantly haploid karyotype allows single-allele targeting for functional gene disruption, making it a favorite for functional genomics. The line maintains critical signaling pathways and is widely applied in CRISPR screens and cell-based assays, providing an optimal background for studying immune receptor pathways.
CD300C encodes an activating immune receptor on myeloid cells that pairs with the ITAM-containing adaptor TYROBP (DAP12). Ligand engagement, possibly phosphatidylserine, triggers DAP12 phosphorylation and recruitment of spleen tyrosine kinase SYK. This initiates a cascade involving PLC??, PKC, and the MAPK/ERK pathway, leading to NF-??B-dependent transcription of cytokines such as TNF, IL-6, and IL-10. The receptor complex also interacts with phosphatases PTPN6 (SHP-1), PTPN11 (SHP-2), and adaptors GRB2 and PLCG2, which regulate phagocytosis and cytokine output.
In HAP1 cells, CD300C disruption yields a clean system for investigating ITAM-mediated signaling, free from the confounding influence of related receptors. The haploid genotype ensures unambiguous gene?Cphenotype linkage, while the leukemic origin retains a relevant cellular context for innate immune studies. This polyclonal knockout model is particularly useful for dissecting CD300C-dependent phagocytosis and cytokine responses, offering reduced clonal bias and enhanced reproducibility in functional analyses.
Applications include functional characterization of CD300C, drug target validation for inflammatory diseases, and screening of immuno-oncology agents targeting ITAM pathways. Compatible assays range from flow cytometry and cytokine profiling to phospho-SYK Western blotting and luciferase-based NF-??B reporter assays. These tools support detailed interrogation of innate immune regulation. For more information, contact Ascent Research.
